Biogen's antisense-based therapy Spinraza (nusinersen) and Roche's oral mRNA splicing modifier Evrysdi (risdiplam). Apitegromab achieved a significant improvement in motor function over placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results